{"TopicDetails": {"type": 0, "ccm2Id": 47032530, "cftId": 0, "identifier": "HORIZON-JU-IHI-2024-08-04-two-stage", "title": "Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies", "publicationDateLong": 1719273600000, "callIdentifier": "HORIZON-JU-IHI-2024-08-two-stage", "callTitle": "Innovative Health Initiative JU Call 8", "callccm2Id": 47032605, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 45177852, "abbreviation": "HORIZON.2.1.7", "description": "Innovative Health Initiative"}, {"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["IHI", "IHU JU", "Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies", "Innovative Health Initiative Joint Undertaking", "Joint Undertaking", "Innovative Health Initiative"], "keywords": ["Health outcomes", "Digital data", "Clinical trials", "Patient care", "Public Private Partnerships (PPP)"], "sme": false, "actions": [{"status": {"id": 31094502, "abbreviation": "Open", "description": "Open"}, "types": [{"typeOfAction": "HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "25 June 2024", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["10 October 2024", "23 April 2025"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3543165": [{"action": "HORIZON-JU-IHI-2024-08-02-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "25 June 2024", "deadlineModel": "two-stage", "deadlineDates": ["10 October 2024", "23 April 2025"], "budgetYearMap": {"2024": 47550000}, "expectedGrants": 1, "minContribution": 14000000, "maxContribution": 14000000, "budgetTopicActionMap": {}}, {"action": "HORIZON-JU-IHI-2024-08-04-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "25 June 2024", "deadlineModel": "two-stage", "deadlineDates": ["10 October 2024", "23 April 2025"], "budgetYearMap": {"2024": 47550000}, "expectedGrants": 1, "minContribution": 12600000, "maxContribution": 12600000, "budgetTopicActionMap": {}}, {"action": "HORIZON-JU-IHI-2024-08-03-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "25 June 2024", "deadlineModel": "two-stage", "deadlineDates": ["10 October 2024", "23 April 2025"], "budgetYearMap": {"2024": 47550000}, "expectedGrants": 1, "minContribution": 5200000, "maxContribution": 5200000, "budgetTopicActionMap": {}}, {"action": "HORIZON-JU-IHI-2024-08-01-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "25 June 2024", "deadlineModel": "two-stage", "deadlineDates": ["10 October 2024", "23 April 2025"], "budgetYearMap": {"2024": 47550000}, "expectedGrants": 1, "minContribution": 15750000, "maxContribution": 15750000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2024"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>The action under this topic must contribute to all of the following outcomes:</p><ul level=\"0\"><li>organisations and institutions involved in the development of therapies for the treatment and management of chronic disease have access to a unifying framework and consensus-based recommendations for:   <ul level=\"1\"><li>using a combination of patient preference information (PPI), clinical outcome assessments (COAs), and digital health technology (DHT)-derived measures to demonstrate the importance to patients of what is being measured by DHT-derived clinical-study endpoints;</li><li>determining, from the patient perspective, what constitutes a minimal clinically important difference (MCID) in a patient-centred, DHT-derived clinical-study endpoint.</li>   </ul> </li><li>new methods for analysing PPI and COA data collected using DHT and for combining data from PPI, COA, and DHT-derived measures are available to researchers;</li><li>a consistent framework for engagement regarding the development and use of patient-centred, DHT-derived clinical-study endpoints is available to industry and stakeholders;</li><li>acceptance of the use of PPI, COAs, and patient-centred DHT-derived measures in addition to or in combination with traditional clinical-study endpoints to provide a robust view of the benefits of a therapy to patients;</li><li>acceptance of the use of patient-centred DHT-derived measures for clinical-study endpoints as reliable evidence for the evaluation of the clinical and economic benefit of therapeutic medicinal products and medical technologies among stakeholders including, but not limited to, patient groups, regulatory bodies, and health technology assessment (HTA) bodies (including the EU Member State Coordination Group on HTA), indicated by a qualification opinion, endorsement, adoption or other approval by each relevant stakeholder group;</li><li>patient-centred, DHT-derived endpoints are implemented along with traditional clinical-study endpoints in clinical studies of therapies to treat chronic diseases, and data from DHT-derived clinical-study endpoints are used in regulatory and reimbursement decision-making.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>Three types of patient-centred information related to how a patient feels and functions contribute to the evaluation of outcomes of a therapy:</p><ul level=\"0\"><li>patient preference information (PPI);</li><li>clinical outcome assessments (COAs) (including patient-reported outcome (PRO) measures);</li><li>digital health technology-derived (DHT-derived) measures.</li> </ul><p>Each of these types of measures can be used to understand patient-centred benefits of therapies (i.e., meaningful improvements in how a patient feels or functions).</p><p>DHT-derived measures can capture patient-centred information about disease symptoms, physical, cognitive, and emotional functions, and experience with therapy. They can measure the status of a patient\u2019s health in ways that may be related to, but often differ from, COAs. For example, DHTs may measure activity intensity but not specific activities. Likewise, DHT-derived measures may detect changes in patient-centred outcomes - such as function - earlier than a patient may notice such a change. For patient-centred DHT-derived measures (i.e., DHT-derived measures that capture how a patient feels and functions) to be useful as endpoints in clinical studies, they must not only be technically validated, but also demonstrate that they measure functions, activities, symptoms, and other impacts of disease and treatment that are important to patients and measure changes in these outcomes that are meaningful to patients.</p><p>PPI, COAs, and DHT-derived measures are different, but complementary, types of patient-centred data. Because these measures are complementary, using these measures in combination will provide a more robust view of the benefits of therapies measured using DHT-derived endpoints from the patient perspective. Combining these complementary measures is necessary to demonstrate the utility of using DHT-derived measures as clinical study endpoints that reflect the value of treatment benefits to patients. Specifically, using these measures in combination may contribute to determining what constitutes a minimal clinically important difference (MCID) in patient-centred DHT-derived endpoints from the patient perspective in clinical studies of therapies to treat chronic diseases. For the purpose of this project, a chronic disease is defined as a long-term health condition that may not have a cure.</p><p>However, despite recent increases in the use of PPI, COAs, and patient-centred DHT-derived measures, there is no unifying framework for understanding the relationships among these measures, nor how they can be used in combination to demonstrate meaningful, patient-centred benefits of therapies for chronic diseases in clinical studies.</p><p>Therefore, uncertainties exist regarding the utility of these measures either alone or in tandem, and the meaningfulness to patients of patient-centred DHT-derived measures when used as clinical study endpoints in the development of therapeutic products (including, but not limited to, pharmaceutical products, combination products, and therapeutic devices) for the treatment of chronic diseases.</p><p>The topic aims to develop a unified framework and consensus-based recommendations for using multiple types of patient-centred information to support the use of DHT-derived endpoints to demonstrate therapeutic benefit. This will ensure that therapies addressing patients\u2019 needs are approved for use and reimbursed at levels that reflect the value of the therapies to patients.</p><p>To fulfil this aim, the action funded under this topic must:</p><p><strong>1.</strong> Develop a framework for using PPI, COAs, and DHT-derived measures in combination for the development, acceptance and implementation of patient-centred DHT-derived clinical-study endpoints in clinical studies of potential treatments for chronic diseases.</p><p>The framework will be designed to ensure that PPI, COAs, and patient-centred DHT-derived measures used in combination will be accepted as reliable evidence to support the use of DHT-derived clinical study endpoints in the evaluation of the clinical and economic benefit of therapeutic drugs and technologies.</p><p>The framework must:</p><ul level=\"0\"><li>include recommendations for using the three types of patient-centred data in addition to or in combination with traditional clinical-study endpoints to provide evidence of the patient-centred benefits of therapeutic drugs and technologies;</li><li>describe the potential relationships among COAs, patient-centred DHT-derived endpoints and other common types of clinical study endpoints;</li><li>identify and address issues related to how and under which circumstances data from PPI and COAs can be used to determine what constitutes a MCID in a patient-centred DHT-derived clinical-study endpoint from the patient perspective;</li><li>identify and address issues related to whether and how data from PPI, COAs, and patient-centred DHT-derived measures can be pooled, including the need for new techniques (including, but not limited to, artificial intelligence, machine learning, and large language models) to jointly analyse pooled data from the different types of measures;</li><li>address issues related to diversity in patient populations (e.g., disease type, disease stage, health literacy, cultural factors, etc.) on the use and results of PPI, COAs, and DHT-derived measures and the ethical and equity implications of patient diversity on the interpretation and utility of patient-centred measures of therapeutic benefit.</li> </ul><p><strong>2. </strong>Develop recommendations for:</p><ul level=\"0\"><li>using quantitative PPI to better understand COA data by demonstrating the relative importance of domains, items, and scores (and changes therein) within a COA instrument and relative to other commonly used endpoints (including endpoints included in relevant core outcomes sets) in clinical studies within the same therapeutic area;</li><li>understanding the relationships between COA data and patient-centred DHT-derived endpoints in diverse therapeutic areas;</li><li>using DHTs (e.g., apps, smart personal devices, smart drug-delivery devices, therapeutic medical technologies, etc.) to collect PPI and COA data;</li><li>using quantitative PPI, COAs, and patient-centred DHT-derived measures in combination to demonstrate the importance to patients of what is being measured by DHTs and determining what constitutes a MCID in a patient-centred, DHT-derived clinical-study endpoint.</li> </ul><p><strong>3.</strong> Conduct at least four use cases to provide evidence to support the framework and recommendations.</p><p>Each use case should address one or more recommendations and all recommendations should be supported by one or more case studies. Applicants should specify the methodology to be applied in each use case and identify how each use case will inform the framework and recommendations. The set of use cases should:</p><ul level=\"0\"><li>include a range of digital measurement domains (e.g., physical activity, sleep, cognition, fatigue, or others) and address differences between passive and interactive DHTs;</li><li>include a range of patient ages (e.g., paediatric, adolescent, younger adults, and older adults);</li><li>address issues related to diversity in patient populations (e.g., disease type, disease stage, health literacy, cultural factors, underserved patient populations);</li><li>address issues related to combining and/or jointly analysing PPI, COA, and/or DHT-derived data using new techniques (including, but not limited to, artificial intelligence, machine learning, and large language models);</li><li>be conducted in partnership with academic medical centres and focus on all of the following areas:   <ul level=\"1\"><li>paediatric radiation oncology;</li><li>lung cancer;</li><li>non-motor and motor symptoms in Parkinson\u2019s disease;</li><li>obesity.</li>   </ul> </li> </ul><p>All use cases must be conducted in a way that is consistent with generally accepted international treatment guidelines in the relevant disease area.</p><p>The precise scope of the use cases will be developed by the full consortium during the preparation of the full proposal at the second stage. Case studies should not involve the <em>de novo</em> development of novel COAs, DHTs, or DHT-derived measures.</p><p><strong>4. </strong>Include robust input from relevant stakeholders. Applicants are expected to specify how relevant stakeholders will be engaged and identify the type of stakeholder required and their expected role in the project. Accordingly, applicants are expected to:</p><ul level=\"0\"><li>engage patients, parents or carers of juvenile patients, and patient organisations as active partners in all aspects of the project to ensure that interaction between patients and research is active, meaningful, and collaborative across all stages of the research process. In this way, research decision making is guided by patients' contributions as partners, recognising their specific experiences, values, and expertise;</li><li>develop the framework and recommendations in consultation with stakeholders, including patient organisations, regulators, health technology assessment (HTA) bodies, and medical organisations to ensure consensus about what is required to demonstrate the patient-centred benefits of a therapy;</li><li>develop a regulatory strategy and interaction plan for evidence generation to support the regulatory qualification of the framework and recommendations and engage with regulators in a timely manner (e.g., national competent authorities, EMA Innovation Task Force, qualification advice).</li> </ul><p><strong>5. </strong>Complement and coordinate with other initiatives including:</p><ul level=\"0\"><li>ongoing and completed European projects (and their successor organisations), and initiatives related to patient engagement and use of digital measurement technologies. Such projects may include, but are not limited to, IMI/IHI projects PRO-active, H2O, PREFER and the PREFER Expert Network, SISAQOL-IMI, IDEA-FAST, MOBILISE-D, IMPROVE, PaLaDin as well as EUnetHTA 21;</li><li>existing frameworks and guidance documents related to patient-focused drug development such as those from FDA and EMA;</li><li>existing frameworks and guidance documents related to the development and deployment of digital clinical measures such as those from the Digital Medicine Society.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>The action under this topic is expected to achieve the following impacts:</p><ul level=\"0\"><li>greater benefit to patients from improved health care by ensuring that DHT-derived measures of how a patient feels and functions are accepted as patient-centred clinical-study endpoints;</li><li>patients having improved access to innovations that meet their needs through the development of new and improved evidence-based methodologies for a more comprehensive assessment of the added value of innovative therapeutic drugs and technologies;</li><li>better informed decision-making at all levels of the health care system (authorities, organisations) to facilitate cost-effective allocation of health resources, continuing innovation, and better health outcomes;</li><li>greater understanding of the relationship between multiple patient-centred measurements including PPI, COAs, and DHT-derived measures and how these measures, when considered together, can provide greater insight into the patient perspective;</li><li>reduced uncertainty regarding the PPI and COA data required to demonstrate the patient-relevance of DHT-derived clinical-study endpoints, and that needed to determine what constitutes a MCID in a patient-centred DHT-derived clinical-study endpoint for use in the development of pharmaceutical products, diagnostics, combination products, and therapeutic devices;</li><li>improved and more efficient engagement between industry and stakeholders in the evaluation of technologies developed using patient-centred DHT-derived endpoints in clinical studies;</li><li>increased speed and efficiency in the development and evaluation of innovative therapeutic technologies.</li> </ul>\n", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\r\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">at      stage 1 of a two-stage Call, the limit for RIA short proposals is 20      pages;</li>\r\n</ul>\r\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">at      stage 2 of a two-stage Call, the limit for RIA full proposals is 50 pages.<b><o:p></o:p></b></li>\r\n</ul>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;&#10;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Horizon Europe Programme Guide</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">.</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes&nbsp;</span></span></span></span><font face=\"Arial\" size=\"2\">and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the <a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/About/AWP/WorkProgramme2024_Amend1.pdf\" target=\"_blank\">IHI JU Work Programme (WP)</a></font></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes&nbsp;</span></span></span></span><font face=\"Arial\" size=\"2\"><span lang=\"EN-US\"><o:p></o:p></span>and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the <a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/About/AWP/WorkProgramme2024_Amend1.pdf\" target=\"_blank\">IHI JU Work Programme (WP)</a></font></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">Specific conditions</span></b></span></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the&nbsp;</span></span></span></span><font face=\"Arial\" size=\"2\">''Conditions of the Calls for proposals and Calls management rules'' section of the <a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/About/AWP/WorkProgramme2024_Amend1.pdf\" target=\"_blank\">IHI JU Work Programme (WP)</a></font></p>\r\n<ul>\r\n    <li>specific conditions on Availability, Accessibility and Affordability (3A) <strong>do not apply to this topic</strong></li>\r\n    <li>JU's right to object to transfer/exclusive licensing</li>\r\n</ul>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<div><b>Where relevant, templates of the reference documents and associated guidance can be found on <a href=\"https://www.ihi.europa.eu/apply-funding/call-documents\">the&nbsp;IHI JU&nbsp;website</a>.</b></div>\r\n<p class=\"MsoNormal\"><b>Regarding the application forms for submitting proposals, the relevant templates and annexes are available to download in the submission system.</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">&nbsp;<span lang=\"EN-US\">The IHI JU 8</span><sup>th</sup>&nbsp;<span lang=\"EN-US\">Call for proposals full topics text is available <a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/IHI_Call8_CallText.pdf\">here</a>.</span></p>\r\n<p class=\"MsoNormal\"><b>Evaluation form (single and two-stage Calls)</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/IHI_Evaluation_form_RIA_UpdateDec2023.pdf\">IHI JU Evaluation form for Research and Innovation Actions&nbsp;</a>(single and two-stage Calls)<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">Proposal Templates Part A and Part B (Research and Innovation Actions &ndash; single-stage and second stage of two-stage procedure)&nbsp;</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;&nbsp;<b><span lang=\"EN-IE\">Proposal template - Part A</span></b><span lang=\"EN-IE\">&nbsp;of the proposal is generated by the IT system in the submission environment (for more information see the HE Part A template&nbsp;</span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span lang=\"EN-IE\">here</span></a><span lang=\"EN-IE\">). In Part A of the proposal applicants insert general information on their proposal (e.g. proposal acronym), details on the participants and the overall proposal budget. <br />\r\nPlease note that&nbsp;<strong>only&nbsp;</strong>Part A of this template is applicable for this call. For Part B, see point below.</span><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\">- <a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Proposal_template_RIA_SP_PartB.pdf\">IHI JU Proposal template (RIA/SP) &ndash; Part B</a>&nbsp;&nbsp;<o:p></o:p></span><b><u><span lang=\"EN-IE\">(applicable to the first-stage of two-stage Calls)</span></u></b></p>\r\n<p class=\"MsoNormal\">-&nbsp;<span lang=\"EN-IE\"><a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/IHI_Proposal_template_RIA_FP_PartB_UpdateJune2024.pdf\" target=\"_blank\">IHI JU Proposal template (RIA/FP) - Part B</a></span>&nbsp;<b><u><span lang=\"EN-IE\">(applicable to the second stage of two-stage Calls)</span></u></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b>Proposal Annexes</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b>- Annex: Type of Participants</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">The&nbsp;<i>&ldquo;type of participants&rdquo;</i>&nbsp;is an IHI specific annex.<o:p></o:p></p>\r\n<p class=\"MsoNormal\">The excel template for:<o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;short proposals (first stage of two-stage calls) can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/IHI_Annex_Type_of_participants_Stage1.xlsx\">here</a>&nbsp;and<o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;full proposals (single-stage calls, and second stage of two-stage calls) can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Annex_Type_of_participants.xlsx\">here</a>&nbsp;<o:p></o:p></p>\r\n<p class=\"MsoNormal\">The instructions on how to fill in this template can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Annex_Type_of_participants_instrucctions.pdf\">here</a>.<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is a compulsory annex, and it must be uploaded as a separate document in the submission system.</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\">This annex is applicable to single-stage and in both stages of two-stage Calls.<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">- Annex: Declaration of in-kind contribution commitment</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">The &ldquo;<i>Declaration of in-kind contribution commitment&rdquo;</i>&nbsp;is an IHI specific annex and it is applicable to the single stage and second stage of two-stage Calls.<o:p></o:p></p>\r\n<p class=\"MsoNormal\">The word document template can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Annex_declaration_in_kind_contribution_commitment%20.pdf\">here</a>.<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is a is a compulsory annex and it must be uploaded as a separate document in the submission system.</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">- Annex: In-kind contributions to additional activities (IKAA)</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">The &lsquo;<i>&rsquo;In-kind contributions to additional activities (IKAA)&rsquo;&rsquo;</i>&nbsp;is an IHI specific annex. The excel template can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/IHI_Annex_declaration_in_kind_contribution_additional_activities_UpdateDec2023.xlsx\">here</a>&nbsp;and the instructions on how to fill in this template can be found&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Annex_declaration_in_kind_contribution_additional_activities_instructions.pdf\">here</a>.<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is an optional annex and&nbsp;it is applicable to the single stage and second stage of two-stage Calls.</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">- Annex: Essential information for clinical studies</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">The information on clinical studies is a Horizon Europe annex.<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is a is a compulsory annex and it must be uploaded as a separate document in the submission system.</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\">If your proposal does not include clinical studies,&nbsp;<u>please upload a statement declaring your proposal does not include clinical studies.</u><o:p></o:p></p>\r\n<p class=\"MsoNormal\">The information on clinical studies annex can be found&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\">here</a>:<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>The annex&nbsp;is applicable to the single stage and second stage of two-stage Calls</i><i><span lang=\"EN-IE\">.</span></i><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">- Annex: Ethics</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">This is a HE annex. Ethics self-assessment should be included in proposal part A. However, in Calls where several serious ethics issues are expected, the characters limit in this section of proposal part A may not be sufficient for participants to give all necessary information. In those cases, participants may include additional information in an annex to proposal part B.&nbsp;<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is an optional annex and&nbsp;it is applicable to the single stage and second stage of two-stage Calls.</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\">- Annex to the budget for the Full Proposal&nbsp;</span></b><o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>This is a compulsory&nbsp;</i><a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/Annex_Budget_for_full_Proposal_TWO_stage_call_UpdateDec2023.xlsx\"><i>Annex</i></a><u>,</u>&nbsp;which complements the budget figures already included in the proposal budget in PART A. Its purpose is to correctly guide the consortium in providing IHI-specific budget items (e.g. IKOP, IKAA, FC PAID, FC RECEIVED, etc.) and to comply with IHI additional eligibility criteria (e.g. 45% industry contribution).<o:p></o:p></p>\r\n<p class=\"MsoNormal\"><i>The annex is applicable to the</i>&nbsp;<i>single stage and second stage of two-stage Calls</i><o:p></o:p></p>\r\n<p class=\"MsoNormal\">&nbsp;&nbsp;<b>Model Grant Agreement (MGA)</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\">&nbsp;-&nbsp;<a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\">HE&nbsp;General MGA v1.0</a><o:p></o:p></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span></h2>\r\n<h2><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\"><b>-&nbsp;<a href=\"https://eur-lex.europa.eu/eli/reg/2021/2085\">Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014</a>&nbsp;&nbsp;(in short Single Basic Act &lsquo;SBA&rsquo; or Council Regulation (EU) 2021/2085).</b><o:p></o:p></p>\r\n<p class=\"MsoNormal\">- <a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/About/AWP/WorkProgramme2024_Amend1.pdf\">IHI JU Work Programme (WP)</a><b><o:p></o:p></b></p>\r\n<p class=\"MsoNormal\">-&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/flmngr/IHI_Strategic_Research_and_Innovation_Agenda_3.pdf\">Strategic Research and Innovation Agenda (SRIA)</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/IHI_Guide_for_Applicants.pdf\" target=\"_blank\">IHI JU Guide for Applicants</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\">-&nbsp;<a href=\"https://www.ihi.europa.eu/sites/default/files/uploads/Documents/Calls/Call_FAQs.pdf\" target=\"_blank\">IHI&nbsp;JU&nbsp;FAQs</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b>Horizon Europe Reference Documents</b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-2-msca-actions_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 2. Marie Sk\u0142odowska-Curie Actions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-3-research-infrastructures_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 3. Research Infrastructures</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 4. Health</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-5-culture-creativity-and-inclusive-society_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 5. Culture, creativity and inclusive society</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-6-civil-security-for-society_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 6. Civil Security for Society</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-7-digital-industry-and-space_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 7. Digital, Industry and Space</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-8-climate-energy-and-mobility_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 8. Climate, Energy and Mobility</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-9-food-bioeconomy-natural-resources-agriculture-and-environment_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 9. Food, Bioeconomy, Natural Resources, Agriculture and Environment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-10-european-innovation-ecosystems_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 10. European Innovation Ecosystems (EIE)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-11-widening-participation-and-strengthening-the-european-research-area_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 11. Widening participation and strengthening the European Research Area</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-12-missions_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 12. Missions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p class=\"MsoNormal\">Please read carefully all provisions below before the preparation of your application.</p>\r\n<p class=\"MsoNormal\">All the information concerning the IHI JU Calls is also published on the&nbsp;<a href=\"https://www.ihi.europa.eu/apply-funding/call-documents\" target=\"_blank\">IHI JU website</a>.&nbsp;&nbsp;&nbsp;<o:p></o:p></p>\r\n<p class=\"MsoNormal\">All the questions pertaining to the IHI JU Calls are to be addressed to&nbsp;<a href=\"mailto:infodesk@ihi.europa.eu\">infodesk@ihi.europa.eu</a>.<o:p></o:p></p>\r\n<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>The submission system is planned to be opened on the date stated on the topic header.</p>\r\n<p>\r\n<p class=\"MsoNormal\">To access the Electronic Submission Service, please click on the submission-button next to the&nbsp;<b>type of action</b>&nbsp;and the&nbsp;<b>type of model grant agreement</b>&nbsp;that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.<o:p></o:p></p>\r\n<p class=\"MsoNormal\">To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.<o:p></o:p></p>\r\n</p>", "links": [{"callIdentifier": "HORIZON-JU-IHI-2024-08-two-stage", "status": "Open", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "HORIZON-JU-RIA", "criterionDescription": "HORIZON JU Research and Innovation Actions", "url": "https://ec.europa.eu/research/participants/submission/manage/screen/submission/create-draft/36939?topic=HORIZON-JU-IHI-2024-08-04-two-stage", "startDate": "Jun 25, 2024 12:00:00 AM", "endDate": "Oct 10, 2024 5:00:00 PM", "mgaDescription": "HORIZON Action Grant Budget-Based", "mgaCode": "HORIZON-AG"}], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Jun 25, 2024 12:00:01 AM", "lastChangeDate": "Jun 25, 2024 12:00:01 AM", "content": "The submission session is now available for: HORIZON-JU-IHI-2024-08-03-two-stage(HORIZON-JU-RIA), HORIZON-JU-IHI-2024-08-01-two-stage(HORIZON-JU-RIA), HORIZON-JU-IHI-2024-08-02-two-stage(HORIZON-JU-RIA), HORIZON-JU-IHI-2024-08-04-two-stage(HORIZON-JU-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": true, "allClosedTopics": false}}}